Bison Wealth LLC cut its holdings in Haleon plc (NYSE:HLN – Free Report) by 17.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 11,136 shares of the company’s stock after selling 2,392 shares during the period. Bison Wealth LLC’s holdings in Haleon were worth $92,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of HLN. FMR LLC boosted its stake in Haleon by 22.2% in the third quarter. FMR LLC now owns 53,951,936 shares of the company’s stock valued at $449,420,000 after acquiring an additional 9,812,040 shares during the last quarter. State Street Corp acquired a new position in shares of Haleon during the 3rd quarter worth about $50,724,000. Alliancebernstein L.P. acquired a new position in shares of Haleon during the 4th quarter worth about $48,960,000. Wellington Management Group LLP acquired a new position in shares of Haleon during the 3rd quarter worth about $42,640,000. Finally, Sculptor Capital LP increased its stake in shares of Haleon by 184.7% during the 1st quarter. Sculptor Capital LP now owns 5,842,838 shares of the company’s stock worth $47,561,000 after purchasing an additional 3,790,310 shares during the last quarter. 6.67% of the stock is owned by institutional investors.
Haleon Trading Up 0.1 %
NYSE:HLN opened at $8.11 on Thursday. The firm’s fifty day moving average is $8.30 and its 200-day moving average is $8.29. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04. Haleon plc has a 52 week low of $7.70 and a 52 week high of $9.05. The firm has a market cap of $37.03 billion, a P/E ratio of 28.96, a P/E/G ratio of 2.12 and a beta of 0.29.
Haleon Announces Dividend
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. HSBC assumed coverage on shares of Haleon in a report on Wednesday. They set a “buy” rating for the company. Argus restated a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.
View Our Latest Stock Report on HLN
Haleon Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories
- Five stocks we like better than Haleon
- Basic Materials Stocks Investing
- United Airlines Soars on Earnings Beat
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Short Selling: How to Short a Stock
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLN – Free Report).
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.